Prognostic significance of pathologic features in localized prostate cancer treated with radical prostatectomy: Implications for staging systems and predictive models

Journal of Clinical Oncology

Volumn 19, Issue 16, 2001, Pages 3692-3705

  Quinn, D I ^a   Henshall, S M ^a   Haynes, A M ^a   Brenner, P C ^a   Kooner, R ^a   Golovsky, D ^a   Mathews, J ^a   O'Neill, G F ^a   Turner, J J ^a   Delprado, W ^a   Finlayson, J F ^a   Sutherland, R L ^a   Grygiel, J J ^a   Stricker, P D ^a  

^a ST VINCENT'S CLINIC   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER STAGING; CANCER SURVIVAL; DIAGNOSTIC VALUE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SCORING SYSTEM; TREATMENT OUTCOME;

EID: 0035881084     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.16.3692     Document Type: Article

References (59)

1. Global cancer statistics
2. Estimates of the worldwide mortality from 25 cancers in 1990
3. International trends and patterns of prostate cancer incidence and mortality
4. Early detection of prostate cancer: II. Estimating the risks, benefits, and costs - American College of Physicians
5. Prostate specific antigen (PSA) testing as screening for prostate cancer: The current controversy
6. Cancer surveillance series: Interpreting trends in prostate cancer - I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates
7. Prostate cancer screening in the Tyrol, Austria: Experience and results
8. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update
9. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma
10. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer
11. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer
12. Biological determinants of cancer progression in men with prostate cancer
13. Prostate cancer is highly predictable: A prognostic equation based on all morphological variables in radical prostatectomy specimens
14. Natural history of progression after PSA elevation following radical prostatectomy
15. Pathologic staging of prostate carcinoma: What are the issues?
16. American Joint Committee on Cancer prognostic factors consensus conference
17. The TNM system of 1992: Comments from the TNM working group
18. How to improve the present TNM staging system
19. American Cancer Society guidelines for the early detection of prostate cancer: Update, June 10:1997
20. Differences between urologists in the United States and Canada in the approach to prostate cancer
21. Tumour control according to pathological variables in patients treated by radical prostatectomy for clinically localized carcinoma of the prostate
22. Pathologic classification of prostate carcinoma: The impact of margin status
23. Should Gleason score 7 prostate cancer be considered a unique grade category?
24. Role of radical prostatectomy in patients with prostate cancer of high Gleason score
25. Adenocarcinoma of the prostate invading the seminal vesicle: Prognostic stratification based on pathologic parameters
26. Cancer control and quality of life following anatomical radical retropubic prostatectomy: Results at 10 years
27. Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy?
28. Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: Epidemiologic significance of annual changes
29. Declining rates of extracapsular extension after radical prostatectomy: Evidence for continued stage migration
30. Minimal or no cancer in radical prostatectomy specimens: Report of 13 cases of the "vanishing cancer phenomenon"
31. Surgical pathology examination of the prostate gland: Practice survey by American Society of Clinical Pathologists
32. Histologic grading of prostate cancer: A perspective
33. The diagnosis and reporting of adenocarcinoma of the prostate in core needle biopsy specimens
34. The TNM classification of prostate cancer
35. Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer
36. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: Intermediate-term results
37. Nonparametric estimation from incomplete observations
38. Regression models and life tables (life tables)
39. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate: II. Radical prostatectomy-treated patients
40. 5-Year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer
41. Assessing the generalizability of prognostic information
42. Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy
43. Cancer incidence and mortality, 1973-1995: A report card for the U.S.
44. Prostate-specific antigen testing in Australia and association with prostate cancer incidence in New South Wales
45. Classification of localized untreated prostate cancer based on 791 men treated only with radical prostatectomy: Common ground for therapeutic trials and TNM subgroups
46. Ability of the 1992 and 1997 American Joint Committee on Cancer staging systems for prostate cancer to predict progression-free survival after radical prostatectomy for stage T2 disease
47. Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin
48. Australian general practitioners' views and use of tests to detect early prostate cancer
49. Self-reported prevalence of prostate-specific antigen testing in South Australia: A community study
50. Prostate cancer testing in SA men: Influence of sociodemographic factors, health beliefs and LUTS
51. Do general practitioners use prostate-specific antigen as a screening test for early prostate cancer?
52. An exploration of screening practices for prostate cancer and the associated community expenditure
53. Health-related quality of life in Australian men remaining disease-free after radical prostatectomy
54. Prostate cancer in Victoria in 1993: Patterns of reported management
55. Prostate carcinoma incidence and patient mortality: The effects of screening and early detection
56. Modified extrafascial radical retropubic prostatectomy technique decreases frequency of positive surgical margins in T2 cancers < 2 cm